Grufity logoGrufity logo

Nurix Therapeutics, Inc. Stock Research

NRIX

8.97USD-0.06(-0.66%)Delayedas of 23 Mar 2023, 12:42 pm

Market Summary

USD8.97-0.06
Delayedas of 23 Mar 2023, 12:42 pm
-0.66%

NRIX Stock Price

NRIX RSI Chart

NRIX Valuation

Market Cap

429.3M

Price/Earnings (Trailing)

-2.38

Price/Sales (Trailing)

11.11

EV/EBITDA

-2.08

Price/Free Cashflow

-2.5

NRIX Price/Sales (Trailing)

NRIX Profitability

EBT Margin

-466.93%

Return on Equity

-59.39%

Return on Assets

-43.28%

Free Cashflow Yield

-40.08%

NRIX Fundamentals

NRIX Revenue

Revenue (TTM)

38.6M

Revenue Y/Y

-8.29%

Revenue Q/Q

-37.14%

NRIX Earnings

Earnings (TTM)

-180.4M

Earnings Y/Y

-23.91%

Earnings Q/Q

-2.21%

Price Action

52 Week Range

7.5219.91
(Low)(High)

Last 7 days

3.1%

Last 30 days

-15.3%

Last 90 days

-21.7%

Trailing 12 Months

-30.6%

NRIX Financial Health

Current Ratio

4.51

NRIX Investor Care

Shares Dilution (1Y)

5.62%

Diluted EPS (TTM)

-3.71

Peers (Alternatives to Nurix Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
2.5T
387.5B
-0.56% -0.91%
25.94
6.37
2.44% -5.35%
2.1T
204.1B
-1.92% -6.89%
30.5
10.08
10.38% -5.25%
1.3T
282.8B
1.63% -25.54%
21.65
4.59
9.78% -21.12%
1.0T
514.0B
-3.36% -34.72%
-376.42
1.99
9.40% -108.16%
MID-CAP
3.6B
258.4M
203.99% 176.76%
-11.9
13.75
24.91% -254.56%
2.3B
9.2B
-18.97% -49.38%
-6.41
0.25
51.67% -98.90%
SMALL-CAP
1.7B
1.7B
-22.36% -14.62%
13.72
0.97
61.79% 371.82%
1.6B
602.5M
-17.77% -52.80%
-2.74
2.63
18.18% -18.59%
1.1B
418.9M
5.51% -56.16%
-2.93
2.57
-9.85% -101.06%
991.7M
478.9M
-11.35% -65.42%
-0.32
2.07
-31.50% -634.70%
954.9M
482.4M
-16.25% -37.64%
-4.12
1.98
33.15% -170.42%
897.6M
50.8M
-34.66% -77.56%
-1.14
17.66
1229.98% -13.59%
788.4M
1.1B
-10.56% -33.33%
27.33
0.72
-5.82% -92.23%
281.8M
10.3M
-24.84% -63.38%
-1.01
27.46
478.23% 7.85%

Financials for Nurix Therapeutics

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-1.6%38,627,00039,240,00038,701,00034,360,00029,750,000
Operating Expenses4.8%222,494,000212,370,000194,110,000170,468,000147,636,000
  S&GA Expenses1.5%37,997,00037,448,00036,043,00033,900,00031,202,000
  R&D Expenses5.5%184,497,000174,922,000158,067,000136,568,000116,434,000
EBITDA-5.0%-175,011,000-166,734,000-150,793,000--
EBITDA Margin-6.6%-4.53-4.25-3.90--
Earnings Before Taxes-5.3%-180,360,000-171,301,000-154,550,000-135,392,000-117,063,000
EBT Margin-7.0%-4.67-4.37-3.99--
Net Income-5.3%-180,360,000-171,345,000-154,471,000-135,452,000-117,194,000
Net Income Margin-6.9%-4.67-4.37-3.99--
Free Cahsflow-5.4%-172,051,000-163,304,000-145,450,000--
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-9.3%417459394438477
  Current Assets-10.3%318355307280311
    Cash Equivalents35.6%64.0048.0042.0079.0081.00
  Net PPE4.0%17.0017.0016.0014.0011.00
Liabilities-3.2%113117128132134
  Current Liabilities4.7%71.0068.0073.0066.0066.00
Shareholder's Equity-11.3%304343267306342
  Retained Earnings-13.2%-401-354-308-263-220
  Additional Paid-In Capital1.2%709701579571564
Accumulated Depreciation6.3%17.0016.0015.00--
Shares Outstanding0.1%47.0047.0045.0045.0045.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-4.6%-159-152-136-135-84.36
  Share Based Compensation14.0%28.0025.0022.0019.0016.00
Cashflow From Investing142.3%27.00-64.33-13.49-65.83-108
Cashflow From Financing-0.5%1171184.00154154

Risks for NRIX

What is the probability of a big loss on NRIX?

92.8%


Probability that Nurix Therapeutics stock will be more than 20% underwater in next one year

89.2%


Probability that Nurix Therapeutics stock will be more than 30% underwater in next one year.

70.5%


Probability that Nurix Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NRIX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Nurix Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for NRIX

Cumulative Returns on NRIX

Which funds bought or sold NRIX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
sold off
-100
-147,000
-
-%
2023-03-06
Rockefeller Capital Management L.P.
added
575
4,000
4,000
-%
2023-02-28
Voya Investment Management LLC
unchanged
-
-37,020
197,980
-%
2023-02-24
NATIXIS
new
-
82,581
82,581
-%
2023-02-15
LAZARD ASSET MANAGEMENT LLC
new
-
11,000
11,000
-%
2023-02-15
Jasper Ridge Partners, L.P.
unchanged
-
-196,093
1,050,910
0.06%
2023-02-15
Metropolitan Life Insurance Co/NY
unchanged
-
-5,321
29,679
-%
2023-02-15
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
added
12.01
-55,000
919,000
-%
2023-02-15
MetLife Investment Management, LLC
unchanged
-
-47,298
255,702
-%
2023-02-15
NOMURA HOLDINGS INC
added
19.52
17,000
3,118,000
0.01%

1–10 of 48

Latest Funds Activity

Are funds buying NRIX calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own NRIX
No. of Funds

Nurix Therapeutics News

Investing News Network

Risankizumab Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis.

Investing News Network,
3 hours ago

The Business Journals

Investing News Network

Zacks Investment Research

Defense World

Reviewing NU (NU) and Its Rivals.

Defense World,
5 days ago

Schedule 13G FIlings of Nurix Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 24, 2023
deep track capital, lp
5.75%
2,717,171
SC 13G
Feb 14, 2023
third rock ventures iii, l.p.
0%
0
SC 13G/A
Feb 14, 2023
deep track capital, lp
4.81%
2,266,569
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
6.9%
3,253,736
SC 13G/A
Feb 14, 2023
redmile group, llc
9.9%
4,899,772
SC 13G/A
Feb 14, 2023
baker bros. advisors lp
9.99%
4,801,954
SC 13G/A
Feb 08, 2023
wasatch advisors inc
-
0
SC 13G
Jan 25, 2023
blackrock inc.
8.8%
4,142,528
SC 13G/A
Jun 10, 2022
deep track capital, lp
5.19%
2,436,164
SC 13G
Feb 14, 2022
third rock ventures iii, l.p.
5.4%
2,422,549
SC 13G/A

NRIX Fair Value

Recent SEC filings of Nurix Therapeutics

View All Filings
Date Filed Form Type Document
Mar 13, 2023
8-K
Current Report
Feb 24, 2023
SC 13G
Major Ownership Report
Feb 15, 2023
4
Insider Trading
Feb 15, 2023
4
Insider Trading
Feb 15, 2023
4
Insider Trading
Feb 15, 2023
4
Insider Trading
Feb 15, 2023
4
Insider Trading
Feb 14, 2023
SC 13G/A
Major Ownership Report
Feb 14, 2023
SC 13G/A
Major Ownership Report
Feb 14, 2023
SC 13G/A
Major Ownership Report

Latest Insider Trading transactions for NRIX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-01-30
Ring Christine
acquired
-
-
1,924
general counsel
2023-01-30
Ring Christine
sold
-9,989
11.7796
-848
general counsel
2023-01-30
van Houte Hans
sold
-10,884
11.7796
-924
chief financial officer
2023-01-30
van Houte Hans
acquired
-
-
2,886
chief financial officer
2023-01-30
Wolff Stefani
acquired
-
-
962
evp and coo
2023-01-30
Wolff Stefani
sold
-4,994
11.7796
-424
evp and coo
2023-01-30
Hansen Gwenn
acquired
-
-
3,207
chief scientific officer
2023-01-30
Hansen Gwenn
sold
-16,632
11.7796
-1,412
chief scientific officer
2022-10-31
Ring Christine
sold
-9,003
12.8805
-699
general counsel
2022-10-31
van Houte Hans
sold
-9,518
12.8805
-739
chief financial officer

1–10 of 50

Arthur T. Sands
240
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

NRIX Income Statement

2022-05-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended6 Months Ended
May 31, 2022
May 31, 2021
May 31, 2022
May 31, 2021
Income Statement [Abstract]    
Collaboration revenue$ 11,432,000$ 7,091,000$ 21,053,000$ 12,102,000
Operating expenses:    
Research and development47,493,00025,994,00090,630,00048,997,000
General and administrative9,654,0007,511,00018,882,00014,041,000
Total operating expenses57,147,00033,505,000109,512,00063,038,000
Loss from operations(45,715,000)(26,414,000)(88,459,000)(50,936,000)
Interest and other income, net314,000171,000525,000489,000
Loss before income taxes(45,401,000)(26,243,000)(87,934,000)(50,447,000)
Provision for income taxes0139,0000210,000
Net loss$ (45,401,000)$ (26,382,000)$ (87,934,000)$ (50,657,000)
Net loss per share, basic$ (1.01)$ (0.60)$ (1.96)$ (1.23)
Weighted-average number of shares outstanding, basic44,898,40943,804,06644,797,23541,318,281
Net loss per share, diluted$ (1.01)$ (0.60)$ (1.96)$ (1.23)
Weighted-average number of shares outstanding, diluted44,898,40943,804,06644,797,23541,318,281

NRIX Balance Sheet

2022-05-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
May 31, 2022
Nov. 30, 2021
Current assets:  
Cash and cash equivalents$ 41,533$ 80,506
Short-term investments255,746215,214
Accounts receivable 6,000
Income tax receivable 204
Prepaid expenses and other current assets9,5109,194
Total current assets306,789311,118
Long-term investments51,538137,189
Operating lease right-of-use assets15,41814,005
Property and equipment, net15,50711,340
Restricted cash901286
Other assets4,1572,833
Total assets394,310476,771
Current liabilities:  
Accounts payable6,1426,650
Accrued expenses and other current liabilities19,73414,549
Operating lease liabilities, current5,4703,847
Deferred revenue, current41,31941,212
Total current liabilities72,66566,258
Operating lease liabilities, net of current portion9,0439,189
Deferred revenue, net of current portion45,86359,022
Total liabilities127,571134,469
Commitments and contingencies (Note 6)
Stockholdersʼ equity:  
Preferred stock, $0.001 par value— 10,000,000 shares authorized as of May 31, 2022 and November 30, 2021; no shares issued and outstanding as of May 31, 2022 and November 30, 2021
Common stock, $0.001 par value— 500,000,000 shares authorized as of May 31, 2022 and November 30, 2021; 45,040,068 and 44,664,371 shares issued and outstanding as of May 31, 2022 and November 30, 2021, respectively4545
Additional paid-in capital578,605563,757
Accumulated other comprehensive loss(3,085)(608)
Accumulated deficit(308,826)(220,892)
Total stockholdersʼ equity266,739342,302
Total liabilities and stockholdersʼ equity$ 394,310$ 476,771